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Abstract
Background: The study objective was to examine cat owner ectoparasiticide purchases in the United States and
estimate the impact of purchase gaps on timely ectoparasite protection administration. These purchase gaps lead to
periods of time when cats are unprotected from ectoparasites.
Methods: Ectoparasiticide purchase transactions for individual cats from 671 U.S. veterinary clinics from January 1,
2017 through June 30, 2019 were evaluated to determine time “gaps” between doses of ectoparasiticides purchased
in a defined 12-month period. Ectoparasiticides examined were topically applied products that contained fluralaner,
fipronil/(S)-methoprene/pyriproxyfen, imidacloprid/pyriproxyfen or selamectin as active ingredients. The duration
of protection following administration of one dose was 8–12 weeks for the fluralaner-containing product and one
month for the other products.
Results: Ectoparasiticide purchase records were obtained from 114,853 cat owners and analysis found that most
owners bought ≤ 6 months of protection during the year, with 61–75% (depending on the product) purchasing just
1–3 months of protection. The size of the average purchase gap was determined for all dose combinations out to 12
months of protection (5–7 doses for fluralaner and 12 doses for the other three products dosed monthly. The largest
gaps occurred between the first and second doses and the second and third doses. Average purchase gaps for the
four different products between doses 1 and 2 ranged from 11.2 to 13.9 weeks and between doses 2 and 3 ranged
from 7.7 to 12.2 weeks. The fraction of purchases separated by gaps and the average length of the gap tended to
decrease with increasing number of doses purchased. Owners purchasing the 8 to 12-week duration product containing fluralaner provided ectoparasite protection (“doses plus gap period”) for a larger proportion of each 2-dose period
compared with owners purchasing products administered monthly.
Conclusions: When cat owners purchase flea and tick medication, gaps between subsequent purchases reduces the
proportion of time ectoparasite protection can be provided. The duration of the gap between doses has an impact on
the effectiveness of flea/tick medication because it inserts a period without flea and tick protection between doses
of flea and tick medication. The gaps between purchases were shorter and the period of ectoparasite protection was
larger for owners purchasing a 12-week product than for owners purchasing a monthly product.
Keywords: Adherence, Cat, Dosing gap, Ectoparasiticide, Doses plus gap period, Purchase Gap
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Background
Fleas, most commonly Ctenocephalis felis felis, routinely
infest indoor and outdoor residing pet cats, causing irritation, hypersensitivity reactions, and transfer of vector
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borne pathogens (VBP) [1–8]. Illness inducing VBPs,
including Bartonella spp., hemoplasmas, and Rickettsia
felis, with infection rates of up to 80% have been reported
in fleas collected from cats [9–11].
Ticks also commonly infest cats causing irritation and
transmission of VBP [6, 8, 12]. In a large survey of ticks
collected from cats in the USA, various tick species were
collected every month of the year, even during winter
months in temperate regions. Ixodes scapularis, Amblyomma americanum and Dermacentor variabilis were
commonly found, but other species including A. maculatum, Haemaphysalis longicornis, Otobius megnini, and
less common Dermacentor spp. and Ixodes spp were
collected [13, 14]. Ticks collected from these cats were
found infected with a variety of VBP including Borrelia
burgdorferi, Anaplasma phagocytophilum, Ehrlichia chaffeensis and spotted fever group Rickettsia spp. [13]. Some
of these tick-borne pathogens are known to infect cats
and are associated with clinical illness [10, 11, 15–20].
Surveys of VBP in cats report high to very high prevalence with Rickettsia spp. and Bartonella spp. being the
most predominant [21–24]. These are zoonotic pathogens and carry associated risks for pet owners and veterinarians [16, 25–28].
Cats exposed to ectoparasites without preventive
measures have higher exposure to VBP and will presumably experience higher rates of vector borne infections.
Consequently, animal health experts routinely recommend ectoparasite control measures for dogs and cats. In
the United States, the Companion Animal Parasite Council (CAPC) recommends flea and tick control administration for all 12 months of the year [4, 29]. Similarly, the
European Scientific Counsel on Companion Animal Parasites (ESCCAP) advises that flea prevention can be necessary year-round with tick prophylaxis during the entire
seasons in which ticks are active [5]. In a recent survey of
veterinarians in the US, most recommended year-round
use of a flea and tick medication for cats [30]. A survey of
veterinarians in the US, UK and Australia recommended
approximately 12 months of flea protection per year and
9–12 months of tick protection for dogs [31].
Ectoparasiticide products are labeled to treat just fleas
or both fleas and ticks on cats. Most of these are dosed
monthly by the pet owner and can be administered either
orally or by topical application. One product containing the isoxazoline-class active ingredient fluralaner
(BRAVECTO® TOPICAL SOLUTION, Merck Animal
Health, Madison, NJ, USA), is labeled for re-administration to cats every 8–12 weeks therefore providing an
extended period of protection compared to monthly retreatments. Most ticks are treated with fluralaner with
12-week redosing, although the product is labelled for
8-week redosing when treating Dermacentor variabilis.
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The effectiveness of any ectoparasite preventive medication is a function of the clinical efficacy of the medication and the actual use of the product by the end user.
The end user is typically a cat owner, and owner behaviors that affect product efficacy include the timing of
dose administration and accurate application when the
dose is required.
Clinical efficacy is determined using well controlled
experiments, with dose administration frequency used
as recommended in precise accordance with label indications [32]. However, studies of dog owner adherence
to veterinary recommendations indicate that actual field
use of these products is typically not precise. Veterinarians tend to recommend year-round ectoparasite protection, however, product purchase records in studies
evaluating owner purchase behavior found that ectoparasite medication purchases provided only 2.9–6.1 months
of ectoparasite prevention when purchased by dog owners over a 12-month period [30, 31, 33, 34].
Some limited data are available regarding real-world
ectoparasiticide purchases and use by cat owners. A survey of 312 dog and cat owners at the Small Animal Hospital of Veterinary Medicine, Lisbon University found
that 63.6% of cats were treated with ectoparasiticides
although most at infrequent intervals [35]. A retrospective study of 1,226 feline patients at a US veterinary
teaching hospital found that only 38% of the cat population received ectoparasite preventatives with 18% receiving treatment year-round and 13% receiving treatment
seasonally [36]. A study of cat owner adherence to veterinary recommendations on ectoparasite prevention using
product purchase records found that over a 12-month
period, cat owners purchased an average of 4.2 months
of ectoparasiticide protection with fluralaner, 3.6 months
with fipronil/(S)-methoprene/pyriproxyfen (FRONTLINE® Gold, Boehringer Ingelheim, Duluth, GA) or 2.8
months with imidacloprid/pyriproxyfen (ADVANTAGE®
II, ELANCO, Greenfield, IN) [37]. These results indicate
that the duration of pet owner adherence to veterinarian
recommendations for ectoparasite control measure is far
shorter than veterinarians recommend. The intrinsic efficacy of ectoparasiticide products can be excellent, however, the actual effectiveness observed by cat owners over
the year will be much lower because there is treatment
underutilization and repeated lapses in adherence to veterinarian recommendations.
This earlier research documents the number of doses
purchased and the associated overall ectoparasite protection months provided during the year; however, these
results do not tell the whole story of ectoparasite protection [33, 34, 37]. These studies do not provide results on
the timing of administration of each dose during the year.
Timing of administration affects the consistent protection
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that an ectoparasiticide product can deliver. To meet the
veterinary recommendation, each dose is ideally given
on time with no delay to deliver 12 contiguous months
of ectoparasite protection. Certain ectoparasites, such as
Ctenocephalides felis felis and Ctenocephalides canis live
in the home environment year-round, and continuous,
uninterrupted ectoparasite control measures are essential for successful elimination of established populations
of these parasites. For example, successful flea control
requires 2–3 months of continuous, timely administration of a highly efficacious flea product to drive an established flea infestation to extinction on the pet and within
the home [38–43]. A missed or delayed ectoparasite protection dose creates a dosing gap that potentially allows
the ectoparasite population to recover and re-establish.
Therefore, gaps in therapy lead to treatment failures and
frustration of well-intentioned pet owner efforts. Gaps
in ectoparasite preventive product purchases provide
evidence of administration delays and reduce ownerobserved product effectiveness, potentially negatively
impacting cat health.
The objective of this study was to evaluate gaps in
owner administration of veterinary prescribed ectoparasiticide products in the United States by analyzing data
on cat owner product purchases. This study also examines the impact of these purchase gaps on the overall
period of ectoparasite protection and the proportion
of time ectoparasite protection can be provided over a
12-month use period. Studies in human and veterinary
medicine report significantly higher adherence rates
for medications with a longer duration of action and
decreased dosing frequency [44–49], therefore, this study
also determines whether there is a difference in purchase
gaps for owners prescribed a longer duration ectoparasiticide for their cat compared with owners prescribed
shorter duration, monthly products.

Methods
Cat owner product purchase records for ectoparasiticide
medications sold at U.S. veterinary clinics were obtained
and analyzed to determine purchase intervals and calculate gaps between dose purchases. Purchase gaps were
used to estimate the extent of timely product administration. A purchase gap was declared if the subsequent
product dose was purchased at a time after the period of
efficacy of a previous dose had ended. Cat owners were
assumed to have administered the product on the day of
purchase, therefore, these data determine the minimum
potential gap size. We were unable to assess a gap if the
cat owner either purchased multiple doses at the same
time or purchased one or more subsequent doses before
completion of the period of efficacy of the previous dose.
The data were also analyzed to calculate: the proportion
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of cat owners who purchased a single dose per year; the
proportion who purchased multiple (> 1) doses per year
without a detectable gap between doses; the proportion
who purchased multiple doses with a gap between doses.
Retrospective topical feline ectoparasiticide purchase
transaction data were obtained for individual cats from
671 veterinary clinics throughout the U.S. for the period
January 1, 2017 through June 30, 2019. Data records
were masked to conceal the identity of the veterinary
clinic and cat owner by using unique numeric identifiers
for clinic, client and pet that allowed purchase records
to be associated for individual owners and cats. Some
cat demographic data, including age and body weight,
were collected. Each ectoparasiticide medication purchase data entry included a date, a product description—
including packaging and doses—and the quantity of
product purchased on that date. Purchases could include
single packs or multi-packs for each product. Transaction records included were for ectoparasite medication
sales made by the clinic to the client in the name of a
single patient. Ectoparasiticide products included were
limited to those that are topically applied and frequently
prescribed within the database. Included were fluralaner topical solution, imidacloprid (with and without
pyriproxyfen), fipronil/S-methoprene/pyriproxyfen and
selamectin (REVOLUTION®, Zoetis, Kalamzoo, MI).
Only transactions by clients who were “pure users”,
meaning that they did not have purchases from multiple
brands, were included in the study. The study period for
each client was defined as the 12 months following their
initial product purchase date. Only cats with purchase
records available for the 12 months following the initial
purchase, regardless of whether more product was purchased or not, were included. Purchases were excluded
from the analysis if the transaction record indicated purchase of more than 24 months of doses in a 12-month
period because these indicate bulk purchase or purchase
of products for more than one cat. Product returned for
credit and purchases for animals other than cats were
also excluded. Fluralaner topical solution has a 12-week
dosing interval for most label indicated ectoparasites,
therefore this product could have a maximum of 5 purchases within a 12-month period, while the monthly
products could have a maximum of 12 purchases within a
12-month period. Fluralaner dosed per label directions to
protect against D. variabilis has an 8-week dosing interval and would be dosed with a maximum of 7 purchases
within a 12-month period.
Gaps were calculated between doses rather than
between purchases of the product, because a purchase could lead to acquisition of one dose or multiple
doses. An algorithm was used to process each purchase
record in the original dataset so that a novel dataset
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was produced as follows: if a purchase record was for a
single dose, the purchase date became the “administration” date for the dose and the protection end date was
calculated based on the product duration; if a purchase
record was for multiple doses, the administration date
of the first dose was the purchase date and the protection end date was calculated from the number of doses
multiplied by the product protection period for each
dose. If there were multiple purchase dates, with different product dose quantities on each purchase date,
then the algorithm was applied similarly. The analysis
assumes that single doses were administered to the cat
when purchased or at the correct consecutive interval
when multiple doses were purchased in a single transaction. This assumption leads to a best-case estimate
of the gap between doses. Owners may, in reality, have
waited or deferred giving either the first or subsequent dose, creating a larger gap than detected in this
analysis.
The total number of doses was calculated for each cat
for the entire 12-month period. In addition, for each
dose purchased during the 12-month period there is an
associated administration date, and a protection end
date calculated using the re-administration interval per
the product label for the purchased product. This subsequently enabled calculation of the gap (in days) between
the end date of the ectoparasite protection provided by
the first administered dose and the recorded administration date for the next dose. A gap was not detectable
when the cat owner purchased multiple doses at the same
time. Based on this method a matrix was developed for
all possible dose gap possibilities. For example, for fluralaner, the possible gaps during the 12 months could be
“Dose 1–2”, “Dose 2–3”, “Dose 3–4” and “Dose 4–5” while
for monthly products, there could be possible dose gaps
starting with “Dose 1–2”, “Dose 2–3” continuing up to
“Dose 11–12”.
The dose gaps described above, e.g. “Dose 1–2”, were
combined across all of the annual purchased doses for
each product, then used to calculate the average gap
(weeks) (Fig. 1). Each possible gap was calculated separately and enabled calculation of gap totals for each different dose, gap totals by total doses, and average gaps for
each product.
The “doses plus gap period” is defined as the time
duration encompassing the dosing intervals for two
consecutive doses plus the average gap between purchases of these doses. The period of ectoparasite protection could then be calculated as the percent of the
time during the doses plus gap period when ectoparasite protection is available.
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1 dose

Dose

2 doses

Dose – gap - Dose

3 doses

Dose – gap – Dose – gap - Dose

4 doses

Dose – gap – Dose – gap – Dose – gap - Dose

5 doses

Dose – gap – Dose – gap – Dose – gap – Dose – gap – Dose

6 doses

Dose – gap – Dose – gap – Dose – gap – Dose – gap – Dose

7 doses

Dose – gap – Dose – gap – Dose – gap – Dose – gap – Dose

8 doses

Dose – gap – Dose – gap – Dose – gap – Dose – gap – Dose

9 doses

Dose – gap – Dose – gap – Dose – gap – Dose – gap – Dose

10 doses

Dose – gap – Dose – gap – Dose – gap – Dose – gap – Dose

11 doses

Dose – gap – Dose – gap – Dose – gap – Dose – gap – Dose

12 doses

Dose – gap – Dose – gap – Dose – gap – Dose – gap – Dose

Fig. 1 Method for calculating average gaps between ectoparasiticide
purchases of 1–12+ doses.* *Average gaps were calculated using
purchase data that demonstrated purchase gaps. + Because
fluralaner topical has a 12-week dosing interval for most parasites on
the product label, a maximum of 5 doses fluralaner topical purchases
were considered for the 12-month period studied and 12 doses of
the monthly products

Statistical summaries (mean, median, standard error,
range) were calculated for age and weight of cats prescribed each study product.

Results
Ectoparasiticide purchase records were obtained for
114,853 cats from 671 veterinary clinics. Regional distribution of participating clinics was: 50% Southeast
(n = 341), 21% Mid-west (n = 142), 15% Southcentral
(n = 98), 8% West (n = 51) and 6% Northeast (n = 39).
Average cat age was 6.4 years (range 0.5–25.0 years) and
the average weight was 4.3 kg (range 0.1–13.6 kgs). Product details for the four feline ectoparasiticide products
examined are included in Table 1.
Most cat owners purchased less than 6 months of
ectoparasite protection regardless of the product used,
with the majority purchasing just 1–3 months of protection while a smaller proportion of cat owners purchased
7–12 months of protection (Tables 2 and 3).
Approximately 45% (n = 51,821) of cat owners purchased just one ectoparasiticide dose in a 12-month
period. Of owners who purchased fluralaner, 67.3%
(n = 18,265) bought one dose which provides each cat
with 12 consecutive weeks of ectoparasiticide protection
in a year. The proportion of owners who purchased just
one dose of a monthly product were 35.5% (n = 3609) for
fipronil/(S)-methoprene/pyriproxyfen, 54.7% (n = 1903)
for imidacloprid/pyriproxyfen and 37.9% (n = 28,044) for
selamectin, respectively. These cats would receive just 4.3
consecutive weeks of protection in a 12-month period
(Table 3).
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Table 1 Information on topical flea and tick control products used in a study of administration gaps
Brand name

Manufacturer

Active ingredients

Indications

Redosing interval

Fleas Ticks Heartworm,
hookworm,
roundworm
BRAVECTO Topical Solution for
Cats

Merck Animal Health

Fluralaner

X

X

12 weeks (or 8 weeks
if D. variabilis is of
concern)

FRONTLINE Gold for Cats

Boehringer Ingelheim

Fipronil/(S)-methoprene/
pyriproxyfen

X

X

Monthly

ADVANTAGE/
Advantage II

ELANCO Animal Health Imidacloprid/Imidacloprid/
pyriproxyfen

X

REVOLUTION

Zoetis

X

Selamectin

Monthly
X

Monthly

Table 2 Proportional purchases of select ectoparasiticides
Owner Yearly Purchases

Fluralaner
(n = 27,138)

Fipronil/(S)-methoprene/
pyriproxyfen
(n = 10,171)

Imidacloprid/pyriproxyfen
(n = 3480)

Selamectin
(n = 74,064)

1–6 months/year

87%

86%

91%

77%

1–3 months/year

67%

67%

75%

56%

4–6 months/year

20%

19%

16%

21%

7–12 months/year

13%

14%

9%

23%

Table 3 Ectoparasiticide doses purchased by cat owners during a 12-month period
Doses purchased per
12 months

Fluralanera
(n = 27,138)

Fipronil /(s)-methoprene/
pyriproxyfen (n = 10,171)

Imidacloprid/pyriproxyfen
(n = 3480)

Selamectin (n = 74,064)

1

18,265 (67.3%)

3609 (35.5%)

1903 (54.7%)

28,044 (37.9%)

2

5216 (19.2%)

1342 (13.2%)

467 (13.4%)

9202 (12.4%)

3

1986 (7.3%)

1846 (18.2%)

239 (6.9%)

8355 (11.3%)

4

1264 (4.7%)

963 (9.5%)

271 (7.8%)

2882 (3.9%)

5

407 (1.5%)

211 (2.1%)

67 (1.9%)

1392 (1.9%)

6

1045 (10.3%)

297 (8.5%)

12,160 (16.4%)

7

141 (1.4%)

37 (1.1%)

1584 (2.1%)

8

411 (4.0%)

94 (2.7%)

3118 (4.2%)

9

264 (2.6%)

16 (0.5%)

1595 (2.2%)

10

50 (0.5%)

12 (0.3%)

526 (0.7%)

11

38 (0.4%)

8 (0.2%)

361 (0.5%)

12

251 (2.5%)

4845 (6.5%)

a

Because fluralaner topical has a 12-week dosing interval for most parasites on the product label, a maximum of 5 doses fluralaner topical purchases were considered
for the 12-month period studied (Note: Up to 7 doses of fluralaner may be required for full year protection in areas where Dermacentor variabilis are of concern)

The percent of purchases made with or without a gap
were determined for cat owners who purchased more
than 1 dose in the 12-month period, and then average gap
length was calculated for each inter-dose interval including doses 1–2, 2–3 … and so on (see Fig. 1) (Table 4).
The proportion of cat owners who purchased more
than 1 dose of their respective product with at least 1 gap
of any duration between doses was 58% (fluralaner), 25%

(fipronil/(s)-methoprene/pyriproxyfen), 38% (imidacloprid/pyriproxyfen), and 31% (selamectin) (Table 4). The
fraction of purchases with a gap between doses and the
average length of the purchase gap generally decreased
as cat owners purchased more doses per year. Cat owners who purchased fluralaner often had the shortest
purchase gaps between each of the doses given in the
12-month period (Fig. 2a–c).
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Table 4 Cat owner ectoparasiticide purchases with and without gaps
Doses purchased

Fluralanera
(n = 27,138)

Fipronil/s)-methoprene/pyriproxyfen
(n = 10,171)

Imidacloprid/pyriproxyfen
(n = 3480)

Selamectin
(n = 74,064)

1 dose
Total N (% of total)

18,265
(67%)

3609
(35%)

1903
(55%)

28,044
(38%)

2–12 doses (%)

(33%)

(65%)

(45%)

(62%)

Total purchasing > 1 dose

8873

6562

1577

46,020

No Gap
N (%)

3699
(42%)

4950
(75%)

975
(62%)

31,587
(69%)

Purchase Gap
N (%)

5174
(58%)

1612
(25%)

602
(38%)

14,433
(31%)

Purchased ≥ 2 doses

8873

6562

1577

46,020

Total with 1–2 dose gap

4301

848

395

8429

% with gap

48%

13%

25%

18%

Ave. Gap (Weeks)

11.2

13.9

13.3

12.9

Purchased ≥ 3 doses

3657

5220

1110

36,818

Total with 2–3 dose gap

1730

485

238

4183

% with gap

47%

9%

21%

11%

Ave. Gap (Weeks)

7.7

12.2

10.0

10.2

1671

3374

871

28,463

Purchased ≥ 4 doses

Total with 3–4 dose gap

647

373

113

3262

% with gap

39%

11%

13%

11%

Ave. Gap (Weeks)

4.5

12.7

10.2

10.2

Purchased ≥ 5 doses

407

2411

600

25,581

Total with 4–5 dose gap

103

239

107

1625

% with gap

25%

10%

18%

6%

Ave. Gap (Weeks)

2.5

10.1

11.1

8.2

2200

533

24,189

Total with 5–6 dose gap

79

37

833

% with gap

4%

7%

3%

Ave. Gap (Weeks)

6.6

5.7

5.6

1155

236

12,029

Purchased ≥ 6 doses

Purchased ≥ 7 doses

T otal with 6–7 dose gap

134

36

2164

% with gap

12%

15%

18%

Ave. Gap (Weeks)

10.0

9.0

9.1

Purchased ≥ 8 doses

1014

199

10,445

Total with 7–8 dose gap

42

7

428

% with gap

4%

4%

4%

Ave. Gap (Weeks)

5.9

3.0

4.3

Purchased ≥ 9 doses

603

105

7327

Total with 8–9 dose gap

35

8

361

% with gap

6%

8%

5%

Ave. Gap (Weeks)

6.2

3.3

5.4

Purchased ≥ 10 doses

339

89

5732

Total with 9–10 dose gap

23

5

276

% with gap

7%

6%

5%

Ave. Gap (Weeks)

5.6

5.6

4.4

Purchased ≥ 11 doses

289

77

5206

Total with 10–11 dose gap

5

3

131

% with gap

2%

4%

3%

Ave. Gap (Weeks)

3.8

2.3

3.2

Purchased 12 doses

251

69

4845

Total with 11–12 dose gap

2

1

40

% with gap

1%

1%

1%

Ave. Gap (Weeks)

2.0

1.0

2.7
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Table 4 (continued)
a

Because fluralaner topical has a 12- week dosing interval for most parasites on the product label, a maximum of 5 doses fluralaner topical purchases were considered
for the 12-month period studied

b

a

Fluralaner topical period of coverage

Dose 1-2 Gap

12

Dose 2-3 Gap

12

Dose 3-4 Gap

12

Dose 4-5 Gap

12

11.2

12

7.7

12

4.5

12

2.4

0

Period of
Coverage

12

10

20

30

40

Dose 1 – 2
Dose 2 – 3
Dose 3 – 4
Dose 4 – 5

% of period
protected

68
76
84
91

Fipronil-(s)-methoprene-pyriproxyfen period of coverage

Dose 1-2 Gap

4.3

Dose 2-3 Gap

4.3

Dose 3-4 Gap

4.3

Dose 4-5 Gap

4.3

Dose 5-6 gap

4.3

Dose 6-7 gap

4.3

Dose 7-8 gap

4.3

Dose 8-9 gap

4.3

Dose 9-10 gap

4.3

Dose 10-11 gap

4.3

Dose 11-12 gap

4.3
0

Weeks
Dose

c

4.3

Dose 2-3 Gap

4.3

10.0

4.3

Dose 3-4 Gap

4.3

10.2

4.3

Dose 4-5 Gap

4.3

Dose 5-6 gap

4.3

Dose 6-7 gap

4.3

Dose 7-8 gap

4.3

3.0
3.3

Dose 8-9 gap

4.3
4.3

d

Dose 10-11 gap

4.3

Dose 11-12 gap

4.3
0

4.3

11.1
4.3
4.3

4.3

% of period
protected
39
46
46
44
60
49
74
72
61
79
90

4.3
4.3
4.3

2.3
1.0

Period of
coverage
Dose 1– 2
Dose 2– 3
Dose 3– 4
Dose 4– 5
Dose 5– 6
Dose 6– 7
Dose 7– 8
Dose 8– 9
Dose 9– 10
Dose 10– 11
Dose 11– 12

4.3

13.3

5.6

4.3

5

10

15

20

25

Weeks
Dose 1

Average Gap

4.3
10.0

4.3

5.9

4.3

6.2

% of period
protected
37
39
40
46
57
46
59
58
61
69
81

4.3

5.6

4.3

3.8

4.3
4.3
10

Dose

Imidacloprid-pyriproxyfen period of coverage

Dose 9-10 gap

4.3
4.3

6.6

5

Dose 2

Dose 1-2 Gap

9.0

12.7
10.1

2.0

Period of
coverage
Dose 1– 2
Dose 2– 3
Dose 3– 4
Dose 4– 5
Dose 5– 6
Dose 6– 7
Dose 7– 8
Dose 8– 9
Dose 9 – 10
Dose 10– 11
Dose 11– 12

4.3
4.3

15

20

25

Weeks

Average Gap

5.7

13.9
12.2

Dose2

Average Gap

Dose2

Selamectin period of coverage

Dose 1-2 Gap

4.3

Dose 2-3 Gap

4.3

10.2

Dose 3-4 Gap

4.3

10.2

Dose 4-5 Gap

4.3

Dose 5-6 gap

4.3

Dose 6-7 gap

4.3

Dose 7-8 gap

4.3

4.3
4.3
4.3

5.6

4.3

9.1
4.3

4.3

Dose 8-9 gap

4.3
4.3

Dose 10-11 gap

4.3

3.2

Dose 11-12 gap

4.3

2.7

0

4.3

8.2

Dose 9-10 gap

Period of
coverage
Dose 1– 2
Dose 2– 3
Dose 3– 4
Dose 4– 5
Dose 5– 6
Dose 6– 7
Dose 7– 8
Dose 8– 9
Dose 9– 10
Dose 10– 11
Dose 11– 12

4.3

12.9

% of period
protected
40
46
46
51
61
49
67
61
66
73
76

4.3

5.4

4.3

4.4
4.3
4.3

5

10

15

20

25

Weeks
Dose 1

Average Gap

Dose2

Fig. 2 Duration of each 2-dose period of coverage, including gap, and % ectoparasite protection

Ectoparasiticide purchase gaps lead to periods of time
when cats do not have ectoparasite protection. This creates a time of increased risk for infestation and exposure
to VBP. Therefore, for each product, the duration of each
“doses plus gap period” was determined (Fig. 2a–c) and
the percentage of time during that period when ectoparasiticide protection could be available, assuming timely
administration, was calculated (Table 5 and Fig. 2a–c).
For cat owners prescribed fluralaner, the percentage of
time when ectoparasiticide was available within each “2
dose plus gap period” gradually increased and was 68%
for 1–2 doses, 76% for 2–3 doses, 84% for 3–4 doses and
91% for 4–5 doses (Table 5 and Fig. 2a). The percentage of time when ectoparasiticides were available within
each “doses plus gap period” for the monthly products
was less than for fluralaner at all comparable dose intervals. For fipronil/(s)-methoprene/pyriproxyfen users, the
percentage of ectoparasite protection for each dosing

period was 38%, 41%, 40%, 46% and 57% for dose periods
of use 1–2, 2–3, 3–4, 4–5, and 5–6, respectively and rose
to 81% by the 12th dose (Table 5 and Fig. 2b). For imidacloprid/pyriproxyfen, the percentage of ectoparasite protection for each dosing period was 39%, 46%, 46%, 44%,
and 60% for doses 2–6 respectively and rose to 90% by
the 12th dose (Table 5 and Fig. 2c). For cats that received
selamectin, the percentage of ectoparasite protection for
each dose plus gap period was 40%, 46%, 46%, 51% and
61%, for dose periods of use 1–2, 2–3, 3–4, 4–5, and 5–6,
respectively, and rose to 76% by the 1 2th dose (Table 5
and Fig. 2d).
The impact of purchase gaps on the percentage of time
that ectoparasite protection was available is shown for
owners who purchased 1–3 months and 1–6 months
of medication in a year, the most common protection
durations purchased (Fig. 3a, b). The fluralaner dosing
interval for most ectoparasites indicated is 12 weeks,
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“Doses plus gap period” is the time from the administration of one dose through the end of the treatment period of the subsequent dose, including the dosing gap, measured in weeks. For Fipronil/(s)-methoprene/
pyriproxyfen , imidacloprid/pyriproxyfen and selamectin, the single dose duration of efficacy was 4.3 weeks. For fluralaner topical the single dose duration of efficacy was 12 weeks per label indication (Note: Up to 7
doses of fluralaner may be required for full year protection in areas where Dermacentor variabilis are of concern)
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Table 5 The proportion of each 2-dose interval with and without ectoparasite protection
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PERIOD OF COVERAGE AND % OF PERIOD
PROTECTED AGAINST ECTOPARASITES BY THE
FIRST 3 MONTHS OF PRODUCT PURCHASED WITH
GAPS

a

Fluralaner-12wk

Product

12

Fluralaner-8wk
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4.3
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PERIOD OF COVERAGE AND % OF PERIOD PROTECTED AGAINST
ECTOPARASITES BY THE FIRST 6 MONTHS OF PRODUCT PURCHASED WITH
GAPS
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Fig. 3 Impact of purchase gap on the period of protection

therefore 1 and 2 doses of fluralaner were compared to
3 and 6 doses of the monthly duration products fipronil/
(s)-methoprene/pyriproxyfen, imidacloprid/pyriproxyfen
and selamectin. Because fluralaner is also labeled for a
8-week dosing interval when necessary for the control of
D. variabilis, 2 and 4 doses of fluralaner were also compared to 3 and 6 doses of the monthly duration products.
The total duration of the 3-month and 6-month “doses
plus gap periods” for each product are shown (Fig. 3a,
b) and for each of these periods the percentage of time
when ectoparasiticide protection could be available was
determined and compared.
These comparisons show that fluralaner, with its
extended duration dosing interval and shorter purchase
gaps, consistently provided longer ectoparasite protection for a larger proportion of each of the “doses plus
gap” periods (Fig. 3a, b). The percentage of ectoparasite protection available during use of the first 12 weeks
or 3 months of product purchased was 100% for fluralaner with the 12-week dosing interval (12 weeks or
2.8 months) and 59% with the 8-week dosing interval,
33% for fipronil/(s)-methoprene/pyriproxyfen, 36% for
imidacloprid/pyriproxyfen and 36% for selamectin. The
percentage of time that ectoparasite protection was available when cat owners purchase 6 months of protection,
two doses of fluralaner administered at 12 week intervals
or 4 doses fluralaner administered at 8 week intervals
or 6 months of the monthly products was 68% for fluralaner administered with 12-week intervals, 58% for fluralaner with the 8-week dosing interval, 32% for fipronil/

(s)-methoprene/pyriproxyfen, 34% for imidacloprid/
pyriproxyfen and 35% for selamectin.

Discussion
Timely administration of ectoparasiticides consistent
with veterinarian recommendations and product labeling
is essential for optimal efficacy and effective ectoparasite
control. Prior studies have made clear that pet owners fall
short of meeting their veterinarians’ recommendations
for ectoparasite protection by purchasing fewer months
per year of ectoparasite protection than advised [30, 31,
33, 34, 37]. The current study expands our understanding of this adherence problem by not only looking at how
much flea and tick medication they purchase in a year,
but how they purchase it. Examining gaps in ectoparasite product purchases can be used to estimate the extent
of delayed administration and its impact on the proportion of time ectoparasite protection might be provided.
The method of looking at gaps in purchases identifies the
minimum amount of time that can occur between the
administration of consecutive doses. Delay in administration or forgetting to administer the medication could
create gaps that are substantially greater than our model
proposes.
Cat owners who have gaps between purchases were
able to provide more weeks of consecutive medication
by using an extended duration product. Not only was
the period of efficacy long enough to resolve a flea infestation, fluralaner provided more consistent medication
delivery through shorter average gaps between doses.
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Cat owners purchase less ectoparasite prevention medication each year than is recommended by veterinarians
[30, 31, 33, 34, 37]. In this study, most cat owners purchased 1–3 months of protection per year. When we look
at ectoparasite medication purchases with gaps between
doses in owners who bought 2 or more doses, gaps were
seen in 25–58% of purchases. Within a brand, the average gap got smaller as cat owners bought more doses per
year. Gaps between doses impact the effectiveness of flea
medications because successful flea control requires 2–3
months of continuous, on-time administration of an efficacious ectoparasiticide in order to eliminate an established flea infestation on the pet and within the home
[38–43]. Measurement of ectoparasite product purchase
gaps provides an estimate of the extent of administration delays, along with assessment of the proportion of
time when cats have or don’t have protection against
ectoparasites.
The gaps between purchases of ectoparasiticide doses
seen in this study are a statement of the minimum possible amount of time between consecutive dose administrations. The reality for some owners is that the doses are
given with some delay after dose purchases, meaning that
the gap in time for administration of follow-up doses are
actually larger than were seen here.
Human patients and pet owners often acquire all of the
prescribed medication for a period of time in one purchase. In this study, over half (57%) of cat owners purchased multiple doses of ectoparasiticide at one time, and
thus may have had purchase gaps that could not be identified. The administration of medication is not observed
once it goes home and some proportion is certainly associated with delayed and missed administration. Studies
in both human and veterinary medicine have shown that
timely administration may not occur even when medication is dispensed in full [35, 44, 45, 47, 48, 50] and up
to 50% of chronic disease medications given to human
patients were not taken as prescribed [51].
For ectoparasite product purchases with a measurable
gap, this gap represents an interruption in redosing and
leads to a lack of ectoparasite protection and possibly,
perceived product failure.
When pet owners purchased ectoparasiticide medication with a gap, this gap was consistently smaller and the
protection time percentage was larger for fluralaner than
for the monthly products. Fluralaner purchase led to cats
getting a proportional protection in their “doses plus gap
period” that ranged up to 91% for any 2-dose use periods
in 12 months. One fluralaner dose is sufficient protection duration to eliminate a flea infestation in a household. Monthly products require three consecutive doses
with no inter-dose gap to be similarly effective. Purchase
profiles and more frequent redosing intervals of monthly
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administered products led to a time of ectoparasite protection that was often less than half that of fluralaner.
Comparisons of these ectoparasiticides and their purchase gaps across the most commonly purchased number
of doses, (3-months and 6-months) show that the proportion of the corresponding period that included ectoparasite protection was consistently greater for fluralaner
than for the monthly products, when dosed at either
the 12-week or 8-week redosing intervals. This is in part
because extended duration fluralaner does not need to be
redosed as often as the monthly medications, and failure
to redose reduces the total amount of time when ectoparasite protection is available. Extended duration medication also allows fewer opportunities for purchase gaps, a
reduced chance of missing a dose and thereby a greater
period of ectoparasite protection. Considering owners
who purchased 6 months of ectoparasiticide with gaps,
cats receiving fluralaner had a proportional protection
period nearly twice as long during the 6 month period
compared to cats receiving monthly ectoparasiticides;
68% for fluralaner with 12-week redosing versus 32%,
34% and 35% for fipronil/(s)-methoprene/pyriproxyfen,
imidacloprid/pyriproxyfen, and selamectin, respectively
(Fig. 3b).
Inconsistent ectoparasiticide administration (failure to
administer the product at correct intervals or to administer the product at all) in the face of continued parasite
exposure is one explanation for parasite lack of efficacy
(LOE) reports [52]. Any gap in the delivery of a monthly
duration product is unacceptable when there is a need to
deliver the 2–3 months of continuous treatment to eliminate a household flea infestation. One benefit of extended
duration flea and tick medication is the duration of effectiveness without redosing [43, 53].
Dosing gaps not only impact the effectiveness of
ectoparasiticide medications but they can also impact
the number of months of coverage that owners purchase
in the following year. Cat owners who purchase multiple doses of ectoparasiticides and also have sizeable gaps
between doses may not be able to use all of their medication within 12 months. The cumulative effect of multiple
dosing gaps may be one reason that owners would report
in a wellness visit that they don’t need more flea and tick
medication in the new year because they have product
left over from the previous year.
Getting pet owners to adhere to veterinary ectoparasite protection recommendations is not easy. Studies
on human patient adherence to prescribed treatment
regimens have shown that simpler, less frequent dosing
regimens improve patient compliance across a variety of
therapeutic classes [44–46, 49, 50, 54–57]. In veterinary
medicine, adherence to veterinary prescribed dosing
intervals tends to be better when dosing is less frequent
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with extended dosing intervals [47, 48]. Studies of dog
and cat owner flea and tick control adherence over a
12-month period show that owners who purchase a
longer duration flea and tick product protected their pets
for more months of the year than owners who purchased
a monthly treatment [33, 34, 37]. The present study similarly demonstrates a benefit of the longer duration flea
and tick product, fluralaner. Cat owners who had gaps
between dose purchases but chose the longer duration
product provided more weeks of consecutive medication necessary for ectoparasite infestation resolution, had
shorter gaps between doses, and an increase in the overall percentage of time with effective ectoparasite protection during each 2-dose use period than cat owners who
purchased a monthly treatment.
Use of a longer duration medication reduces treatment
interruptions which should improve the overall effectiveness and result in decreased exposure to VBP while
providing greater satisfaction with efforts to remove
ectoparasites.
In spite of the size of the population examined, this
study was limited by the relatively small number of cat
owners who purchased more than 6 months of ectoparasite control The percent period of protection was
assessed for fluralaner at 8-week and 12-week redosing
intervals showing up to 6 months of protection, which
is the most commonly purchased number of multiple
dose purchases for all products examined. In addition,
on-time administration of ectoparasiticides purchased in
multi-dose transactions could not be confirmed. Finally,
some cat owners may purchase some products through
non-veterinary channels (over-the-counter sales or
online pharmacies) that are not captured in this transaction database analysis and thus could supplement the
doses purchased from veterinarians.

Conclusions
Cat owners fail to adhere to veterinary ectoparasiticide
protection recommendations because they often purchase only 1–3 months of protection per year (56–75%)
and frequently have gaps between ectoparasiticide dose
purchases (25–58% who purchase 2 doses or more per
year). Gaps between doses of ectoparasiticidal products
could lead to treatment failures and owner frustration
with ectoparasite control. On average, an extended duration flea and tick treatment achieves more consecutive
months of ectoparasite protection. Each 12-week dose of
fluralaner delivers a longer (up to 3X) period of medication activity without re-dosing, compared to a monthly
ectoparasiticide product. While the current ectoparasiticide products have proven efficacy against fleas ± ticks,
their effectiveness is greatly impacted by dosing gaps.
The use of an extended duration ectoparasiticide and the
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reduced need for re-dosing reduces the impact of missed
or delayed doses on annual ectoparasite protection.
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